Intercept Pharmaceuticals Appoints Richard Kim as Senior Vice President, Commercial Head of U.S.

23-Jul-2015 - USA

Intercept Pharmaceuticals, Inc. announced the appointment of Richard Kim as Senior Vice President, Commercial Head of U.S.

Mr. Kim most recently served as General Manager, Hepatitis C, Worldwide Commercialization at Bristol-Myers Squibb, where he led the worldwide strategy and commercialization for daclatavir and asunaprevir. During his tenure at Bristol-Myers Squibb, Mr. Kim held multiple positions of increasing responsibility over more than ten years, co-leading a national Cardiovascular and Metabolics sales force and managing both U.S. and global commercial activities for a portfolio of oncology therapies. Prior to joining Bristol-Myers Squibb, Mr. Kim worked at Schering-Plough (now a part of Merck & Co.) holding various positions in Canada, the U.S., and Australia.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances